NasdaqGM:RAPPPharmaceuticals
Can Rapport Therapeutics’ (RAPP) RAP-219 Data Details Reframe Its Neurology Pipeline Valuation?
Rapport Therapeutics announced that it will present detailed Phase 2a data for its lead candidate RAP-219 in focal onset seizures, including efficacy and safety outcomes, at the American Epilepsy Society Annual Meeting in Atlanta on December 5–9, 2025.
A particularly interesting angle for investors is the planned disclosure of how RAP-219’s efficacy varies over the first month of treatment and across different baseline disease severities, offering a deeper look at its potential clinical...